全文获取类型
收费全文 | 96080篇 |
免费 | 9391篇 |
国内免费 | 5655篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 4049篇 |
妇产科学 | 390篇 |
基础医学 | 7685篇 |
口腔科学 | 508篇 |
临床医学 | 8501篇 |
内科学 | 24415篇 |
皮肤病学 | 625篇 |
神经病学 | 1524篇 |
特种医学 | 3241篇 |
外国民族医学 | 20篇 |
外科学 | 24444篇 |
综合类 | 15016篇 |
现状与发展 | 31篇 |
一般理论 | 2篇 |
预防医学 | 2766篇 |
眼科学 | 1272篇 |
药学 | 6858篇 |
38篇 | |
中国医学 | 4546篇 |
肿瘤学 | 5078篇 |
出版年
2024年 | 168篇 |
2023年 | 1625篇 |
2022年 | 2049篇 |
2021年 | 3690篇 |
2020年 | 3790篇 |
2019年 | 3611篇 |
2018年 | 3609篇 |
2017年 | 3709篇 |
2016年 | 4061篇 |
2015年 | 3737篇 |
2014年 | 6126篇 |
2013年 | 6438篇 |
2012年 | 5172篇 |
2011年 | 6073篇 |
2010年 | 5028篇 |
2009年 | 4990篇 |
2008年 | 5112篇 |
2007年 | 5320篇 |
2006年 | 5251篇 |
2005年 | 4544篇 |
2004年 | 3675篇 |
2003年 | 3164篇 |
2002年 | 2666篇 |
2001年 | 2358篇 |
2000年 | 1983篇 |
1999年 | 1586篇 |
1998年 | 1470篇 |
1997年 | 1283篇 |
1996年 | 1178篇 |
1995年 | 981篇 |
1994年 | 1030篇 |
1993年 | 691篇 |
1992年 | 788篇 |
1991年 | 583篇 |
1990年 | 475篇 |
1989年 | 422篇 |
1988年 | 403篇 |
1987年 | 306篇 |
1986年 | 259篇 |
1985年 | 296篇 |
1984年 | 243篇 |
1983年 | 150篇 |
1982年 | 187篇 |
1981年 | 157篇 |
1980年 | 129篇 |
1979年 | 109篇 |
1978年 | 109篇 |
1977年 | 89篇 |
1976年 | 100篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
11.
12.
目的 探讨Hsa-miR-4282在肝癌细胞系SMMC-7721中的表达及其对细胞生长的影响。方法 采用实时荧光定量PCR法检测Hsa-miR-4282在人正常肝上皮细胞系HL-7702和人肝癌细胞系MHCC97-H、SMMC-7721,以及 20例肝癌组织及其相应癌旁组织中的表达。采用瞬时转染法将Hsa-miR-4282 mimics(上调组)和Hsa-miR-4282 inhibitor(下调组)分别转染肝癌SMMC-7721细胞,上调组和下调组分别设置相应阴性对照组。转染后采用MTT法检测细胞增殖能力,平板克隆形成实验检测细胞克隆形成能力,流式细胞仪检测细胞凋亡能力。结果 Hsa-miR-4282在肝癌组织、肝癌细胞MHCC97-H及肝癌细胞SMMC-7721中的表达均低于癌旁组织及正常肝细胞HL-7702(P<0.05)。MTT实验结果显示,Hsa-miR-4282上调后肝癌SMMC-7721细胞的OD值低于其阴性对照组,而下调后OD值高于其阴性对照组 (P<0.05)。平板克隆形成实验显示,下调组的细胞克隆数高于其阴性对照组[(240±7) 个 vs (191±10) 个,P=0.005)],而上调组细胞克隆数低于基阴性对照组[(146±10) 个 vs (193±12) 个,P=0.013)]。流式细胞仪检测结果显示,Hsa-miR-4282上调组细胞凋亡率较其阴性对照组升高[(23.89±1.89)% vs(16.6±1.14)%,P=0.009)],下调组细胞凋亡率较期阴性对照组降低[(14.98±0.46)% vs (17.79±0.73)%,P=0.010]。结论 Hsa-miR-4282上调可抑制肝癌SMMC-7721细胞增殖,促进细胞凋亡,可能与肝癌的发病机制有关。 相似文献
13.
14.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
15.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献
16.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
17.
[目的]数据挖掘法分析周珉教授治疗原发性肝癌的中医用药规律,探讨相关病机并进行经验总结。[方法]收集2016年2月—2018年5月周珉教授门诊期间治疗原发性肝癌的方剂,运用"中医传承辅助系统(V2.50)"进行数据挖掘,并结合周珉教授临床经验,进行原发性肝癌病机探讨及用药规律分析。[结果]共收集治疗原发性肝癌方剂176首,涉及中药235种,列出方剂中的高频药物及组合规律。[结论]总结原发性肝癌以"湿热痰毒、气阴两伤"为基础病机,"清热化湿、健脾养阴"治则贯穿原发性肝癌治疗始末,同时,根据疾病不同发展阶段及治疗措施,权衡"扶正"与"祛邪"的主次分配,斟酌应用"攻毒散结""行气化瘀"等治法,以达到改善患者生活质量、延缓疾病进展的目的。 相似文献
18.
Lara Silveira Abdo Aguiar Rita de Cssia Rossini Lismary Aparecida de Forville Mesquita Gerson Dellatorre 《Journal of Cosmetic Dermatology》2019,18(6):1733-1736
Depigmented lesions may occur as postinflammatory sequelae of subacute cutaneous lupus erythematosus (SCLE), leading to great psychosocial impact. A 53‐year‐old male patient presented with post‐SCLE depigmented facial lesions after five years of disease stability. We proposed surgical treatment with melanocyte‐keratinocyte transplantation procedure (MKTP), and after five months the patient achieved 90% repigmentation, without Koebner phenomenon (KP). In theory, KP is a possible complication of MKTP procedure since the preparation of the receptor area involves the use of dermabrasion. In an attempt to avoid it, we suggest to maintain the treatment of the underlying disease and wait for a minimum period of disease stability before the procedure. 相似文献
19.
B Maybury A Powell-Chandler N Kumar 《Annals of the Royal College of Surgeons of England》2015,97(3):e37-e38
We report two British cases of liver abscess, due to Klebsiella pneumoniae and associated with synchronous infection elsewhere, which required liver resection for definitive treatment. They illustrate the geographic spread of aggressive K pneumoniae liver infection and demonstrate the importance of early aggressive treatment. 相似文献
20.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献